{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-055725","form_type":"8-K","ticker":"FLGT","cik":"0001674930","company_name":"Fulgent Genetics, Inc.","filed_at":"2021-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.600279+00:00","generated_at":"2026-06-28T10:47:51.191762+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Fulgent Genetics Q3 revenue $227.9M (+124% YoY); raises FY revenue guidance to $930M","bullets":["Revenue $227.9M (+124% YoY); core revenue $40.1M (+292% YoY).","GAAP net income $122.5M ($3.93 diluted EPS); non-GAAP net income $126.3M ($4.05 per share).","Adjusted EBITDA $167.3M; cash & investments $877.3M as of Sep 30, 2021.","Full-year 2021 revenue guidance raised to $930M from $800M.","Billable tests ~2.2M in Q3, more than double Q3 2020."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-055725","json":"https://secwatch.observer/filing/0001564590-21-055725.json","markdown":"https://secwatch.observer/filing/0001564590-21-055725.md","text":"https://secwatch.observer/filing/0001564590-21-055725.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674930/000156459021055725/0001564590-21-055725-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674930/000156459021055725/flgt-8k_20211109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:47:51.191762+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}